MedTrace Logo

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

NCT01705379 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-12-01

No results posted yet for this study

Summary

A multicenter, single arm, postmarketing surveillance study. This study is a postlicensure requirement of the Philippine Food and Drug Administration (FDA) to provide continued safety evaluation of MenACWY-CRM in Philippine individuals 2 years of age and older, receiving MenACWY-CRM vaccination according to routine clinical practice and prescribing information.

Conditions

  • Meningococcal Disease

Interventions

BIOLOGICAL

Novartis Meningococcal ACWY Conjugate Vaccine

Immunization

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705379 on ClinicalTrials.gov